X
41.48
-0.14 (-0.34%)
| 前收盘价格 | 41.62 |
| 收盘价格 | 41.82 |
| 成交量 | 763,832 |
| 平均成交量 (3个月) | 865,359 |
| 市值 | 3,205,367,296 |
| 价格/销量 (P/S) | 448.11 |
| 股市价格/股市净资产 (P/B) | 5.89 |
| 52周波幅 | |
| 利润日期 | 3 Nov 2025 |
| 营业利益率 (TTM) | -969.84% |
| 稀释每股收益 (EPS TTM) | -3.22 |
| 总债务/股东权益 (D/E MRQ) | 1.23% |
| 流动比率 (MRQ) | 17.66 |
| 营业现金流 (OCF TTM) | -196.85 M |
| 杠杆自由现金流 (LFCF TTM) | -128.49 M |
| 资产报酬率 (ROA TTM) | -22.03% |
| 股东权益报酬率 (ROE TTM) | -31.60% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Xenon Pharmaceuticals Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.1
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.0 |
| 平均 | 0.13 |
|
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.14% |
| 机构持股比例 | 103.51% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Avoro Capital Advisors Llc | 30 Sep 2025 | 5,400,000 |
| Holocene Advisors, Lp | 30 Sep 2025 | 1,976,553 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 62.00 (JP Morgan, 49.47%) | 购买 |
| 中 | 55.00 (32.59%) | |
| 低 | 48.00 (Wells Fargo, 15.72%) | 购买 |
| 平均值 | 55.00 (32.59%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 42.91 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| JP Morgan | 09 Jan 2026 | 62.00 (49.47%) | 购买 | 42.15 |
| 18 Nov 2025 | 60.00 (44.65%) | 购买 | 40.61 | |
| Wells Fargo | 11 Dec 2025 | 48.00 (15.72%) | 购买 | 43.66 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合